Frontiers in Medicine

Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study

By Inga Catharina Brouer, Aida Zani, Henning Olbrich, Ralf Joachim Ludwig, Diamant Thaçi

Figure 1. Flowchart of study inclusion. — Figure 1. Flowchart of study inclusion.Flowchart of study inclusion.Brouer et al.

Cohort study of 8,564 peopleInterventions

Declared ties to: TriNetX, Novartis, Sanofi and 18 more

The paper

Inga Catharina Brouer, Aida Zani, Henning Olbrich, Ralf Joachim Ludwig, Diamant Thaçi

University of Lübeck

Frontiers in Medicine, 31 Aug 2026

doi.org/10.3389/fmed.2026.1909537 PubMed 42741157

Cardiology and Therapy4 Oct 2026
Low-carb telemedicine links to fewer cardiovascular events
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Neurology Genetics4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk